An Open Label, Multi-centre, Post Marketing Surveillance to Observe the Safety and Effectiveness of ARNUITY Administered in Patients With Asthma in Usual Practice
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 29 May 2019 Status changed from not yet recruiting to recruiting.
- 02 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 27 Jul 2018 New trial record